Advertisements

Novaclav

Quick links to important sections

Novaclav

Selected form

Advertisements

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Novaclav

What is Novaclav?

Novaclav is a combination antibiotic medication composed of two active ingredients: amoxicillin and clavulanic acid. It belongs to the class of medicines known as penicillin-group antibiotics. This combination is designed to treat various bacterial infections by addressing the mechanisms that some bacteria use to resist standard antibiotic treatment.

Composition and Mechanism

The effectiveness of Novaclav is derived from the synergistic action of its two components:

  • Amoxicillin: A broad-spectrum antibiotic that works by interfering with the ability of bacteria to form protective cell walls, which are essential for their survival.
  • Clavulanic Acid: While it does not have significant antibiotic activity on its own, it acts as a beta-lactamase inhibitor. It prevents certain bacteria from producing enzymes that would otherwise break down and deactivate the amoxicillin.

By protecting the amoxicillin from enzymatic degradation, the clavulanic acid allows the antibiotic to remain effective against a wider range of bacteria, including strains that have developed resistance to amoxicillin alone.

Clinical Applications

Novaclav is utilized for the management of several types of bacterial infections, provided they are caused by organisms susceptible to this specific combination. Common areas of application include:

  • Respiratory Tract Infections: Such as sinusitis, tonsillitis, and bronchitis.
  • Urinary Tract Infections: Including cystitis and kidney infections.
  • Skin and Soft Tissue Infections: Such as cellulitis or infections resulting from animal bites.
  • Dental Infections: Particularly dental abscesses.

As an antibacterial agent, Novaclav is effective only against infections caused by bacteria; it does not treat viral infections, such as the common cold or influenza.

Regulatory References

  1. Amoxicillin; Clavulanate Potassium (Compound CID 23695837)
Advertisements

What side effects are possible with Novaclav?

Possible side effects and safety information

Novaclav's safety profile is formally organized by regulatory authorities, classifying possible adverse reactions based on their frequency and the physiological systems affected. This information reflects officially documented findings from clinical use.


Frequency-Classified Adverse Reactions

The most commonly reported adverse reactions primarily involve the gastrointestinal system and are classified as follows in regulatory documents:

Classification Examples of Adverse Reactions (SOC)
Very Common Diarrhoea
Common Nausea, Vomiting, Mucocutaneous candidiasis (thrush)
Uncommon Dizziness, Headache, Rash, Reversible increase in liver enzymes (ALT/AST)
Rare Reversible leucopenia, Erythema multiforme

System and Safety Considerations

The most frequently affected System-Organ Classes (SOCs) include Gastrointestinal Disorders (diarrhoea, nausea), Hepatobiliary Disorders (enzyme increases, hepatitis), and Skin and Subcutaneous Tissue Disorders (rash, pruritus). Hypersensitivity reactions are generally noted to be more likely to occur at the start of treatment.

Serious Adverse Reactions officially documented include severe hypersensitivity (e.g., Anaphylaxis), severe hepatic dysfunction (e.g., Cholestatic Jaundice), and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome.

Safety-Related Restrictions prohibit the use of Novaclav in individuals with a history of severe hypersensitivity to any beta-lactam agent (penicillins or cephalosporins), or a prior history of jaundice/hepatic dysfunction associated with this combination. Caution is also noted for patients with renal impairment, and the drug is contraindicated in patients with Infectious Mononucleosis.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Novaclav (Amoxicillin and Clavulanate) is associated with officially documented manifestations, primarily affecting the gastrointestinal and renal systems. High doses of the amoxicillin component increase the potential for serious complications.

Documented Overdose Manifestations

System Manifestations Listed in Regulatory Documents
Gastrointestinal Vomiting, diarrhea, stomach/abdominal pain
Central Nervous System Convulsions (fits), hyperactivity, drowsiness
Renal/Urinary Amoxicillin crystalluria, oliguric renal failure

Severe Outcomes and Required Actions

The most serious documented outcomes involve oliguric renal failure resulting from interstitial nephritis or crystalluria. Patients with existing impaired renal function are noted to have a higher risk of developing convulsions and high blood levels of the drug components during overdosage.

Immediate medical action is required for all suspected overdoses. You must seek immediate medical attention and contact a hospital emergency department or Poison Control Centre, even if no symptoms are present. Emergency services (e.g., 911) must be contacted immediately if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Treatment is supportive and symptomatic; both active components can be removed from circulation by hemodialysis.

Advertisements

Therapeutic Uses of Novaclav

What Novaclav Treats: Main Uses and Benefits

Novaclav is a combination antibiotic commonly used to help with bacterial infections, particularly in situations where resistance to standard antibiotics is a concern. Its primary therapeutic value is relevant for managing infections in challenging clinical contexts due to its composition.

The combination of amoxicillin and clavulanic acid is relevant for conditions characterized by periods of heightened symptoms across several therapeutic areas, including: respiratory tract infections, such as Community-Acquired Pneumonia and Acute Bacterial Sinusitis; ENT infections like Acute Otitis Media; skin and soft tissues infections (e.g., cellulitis and animal bites); and genitourinary tract infections.

This approach provides support that helps ease the overall symptom burden of these infections, which may include systemic signs like fever and localized discomfort, such as pain and swelling. It supports the patient during difficult episodes by assisting with maintaining functional stability when symptoms interfere with routine activities, and may assist in being applied across domains where additional symptomatic support is needed.


Quick Fact: Relief for Localized Inflammatory Distress The medication is commonly used when supportive symptom management is appropriate for symptoms of localized inflammatory distress, helping to ease pain and swelling associated with conditions like cellulitis or acute sinusitis.

Advertisements

Eligibility and Restrictions for Use

The eligibility for Novaclav (amoxicillin and clavulanate) is officially defined by specific prohibitions and restrictions documented in regulatory labeling. The medicine is contraindicated and must not be used by any patient with a history of serious hypersensitivity (allergic) reactions to its components or to any other penicillin-class (beta-lactam) antibacterial drug. It is also prohibited for patients with a previous history of liver problems, specifically cholestatic jaundice or hepatic dysfunction, associated with prior use of amoxicillin/clavulanate.


Age and Condition Restrictions

Population Group Regulatory Status and Constraint
Pediatric Patients Approved for use in infants (under 12 weeks) and children; however, those under 40 kg must not use certain tablet strengths due to differences in formulation ratios.
Renal Impairment Severe renal impairment ( CrCl < 30 mL/min) prohibits the use of the 875 mg tablet strength and extended-release forms.
Hepatic Impairment Use requires caution and regular monitoring of liver function, as the drug is cleared by the liver.
Pregnancy/Lactation Classified as Pregnancy Category B. Use during pregnancy is permitted only if clearly needed. Caution is required in nursing mothers.
Other Conditions Use must be avoided in patients with or suspected of having Infectious Mononucleosis. Formulations containing aspartame are not eligible for patients with Phenylketonuria (PKU).
Advertisements

What should I know about interactions with other medicines?

The official regulatory interaction profile for Novaclav (Amoxicillin/Clavulanic acid) is defined by documented pharmacokinetic and pharmacodynamic interactions.

Documented Drug-Drug and Pharmacokinetic Interactions

  • Co-administration with Probenecid is not recommended. This substance inhibits the renal tubular secretion of the Amoxicillin component, resulting in increased and prolonged plasma concentrations (exposure) of Amoxicillin.
  • The combination with Oral Anticoagulants (such as Warfarin) may increase the prolongation of prothrombin time (INR), which necessitates appropriate monitoring of coagulation parameters.
  • Concurrent use with Allopurinol is associated with an increased incidence of rash (a pharmacodynamic additive effect).
  • Novaclav, in common with other broad-spectrum antibiotics, may reduce the efficacy of concurrent Oral Contraceptives.

Administration and Condition-Specific Cautions

  • The official labeling includes a timing-based requirement: the absorption of the clavulanate component is enhanced when the medicine is administered at the start of a meal.
  • Use of Novaclav must be avoided in patients with Infectious Mononucleosis due to the associated risk of a morbilliform rash.
  • Monitoring of liver function tests is recommended for patients with pre-existing hepatic impairment.
Advertisements

Mechanism of Action

Targeting Bacterial Cell Wall Synthesis

This core mechanistic domain is where Amoxicillin acts by permanently binding to bacterial Penicillin-Binding Proteins (PBPs) , the enzymes responsible for constructing the cell wall. This essential inhibition initiates a cascade of cell wall failure, followed by the death and lysis of susceptible bacteria, resulting in a bactericidal effect.


Overcoming Microbial Defense Mechanisms

This domain focuses on the action of Clavulanic Acid, a targeted inhibitor of bacterial beta-lactamase enzymes. By forming a stable, irreversible bond with these enzymes, Clavulanic Acid effectively neutralizes the primary bacterial defense against Amoxicillin, thereby increasing the spectrum of bacteria against which Amoxicillin is effective.


The Lytic Physiological Cascade

This mechanism describes the system-level consequence of the molecular interactions. The dual action of protecting Amoxicillin and inhibiting PBPs triggers the bacteria's own autolytic enzymes, resulting in the rapid destruction and rupture of the microbial cell. This lytic process produces the key physiological outcome of reduction of viable bacteria within affected tissues.

Advertisements

Dosage and Administration Information

How to Use Novaclav: Official Administration Guidelines

Novaclav (Amoxicillin and Clavulanic acid) is for oral use only. The prescribed dosage, frequency, and duration of therapy are specifically defined and must be followed exactly.

Standard Dosing and Administration

The medicine is supplied as film-coated tablets and powder for oral suspension. The dosage is based on the amoxicillin component.

Adult Dosing Regimen (≥ 40 kg) Frequency Notes on Administration
875 mg/125 mg (Amoxicillin/Clavulanic acid) Every 12 hours (BID) Used for severe infections and respiratory tract infections.
500 mg/125 mg (Amoxicillin/Clavulanic acid) Every 12 hours or Every 8 hours (TID) The every 12 hour regimen is often associated with less diarrhea.

Administration Timing: To minimize potential gastrointestinal intolerance and optimize the absorption of clavulanic acid, Novaclav should be administered at the start of a meal.

Duration and Special Use Constraints

  • Treatment Course: The usual course of therapy is 7 to 10 days. Treatment should not be extended beyond 14 days without medical review.
  • Pediatric Dosing: For children weighing less than 40 kg, dosing is calculated based on body weight (mg/kg) using the amoxicillin component and is typically divided every 12 or every 8 hours.
  • Renal Adjustment: Dose modification is required for adults with impaired kidney function (creatinine clearance ≤ 30 mL/min), and the 875 mg/125 mg tablet is generally not recommended in this patient group.
  • Suspension Preparation: The powder for oral suspension must be reconstituted with water and shaken well before each dose. It is crucial to measure the exact prescribed volume accurately.
Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Novaclav

Evidence for Use in Acute Otitis Media (AOM) and Sinusitis

The research base for Novaclav's use in ear and sinus infections, which are conditions characterized by fluctuating or episodic manifestations, relies heavily on Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies have primarily been was studied for two key populations: children (infants to 5 years) and adult outpatients. Researchers examined outcomes related to physical discomfort, tracking the time until symptom resolution and the number of participants with treatment failure over short periods.

Findings describe patterns observed in the studies when comparing the combination product to amoxicillin alone or to placebo. Some research monitored measured outcomes observed across the combination product and certain other oral antibiotics. However, other trials observed no statistically significant difference in the outcome when comparing the combination product to placebo in adults with clinically diagnosed acute rhinosinusitis. Research is ongoing to investigate optimal ingredient ratios to address patient-reported outcomes describing perceived discomfort.

Evidence for Use in Lower Respiratory Tract Infections (e.g., CAP)

The research for lower respiratory tract infections, such as Community-Acquired Pneumonia (CAP), has relied on Systematic Reviews and Network Meta-Analyses. These studies explored outcomes related to systemic or functional imbalance, tracking early clinical response, final clinical resolution status (up to Day 30), and hospital readmission rates. Some comparative systematic reviews reported that evidence was insufficient to show a difference in clinical resolution when the combination product was compared to amoxicillin alone in broad study populations. These analyses primarily research described measured parameters related to clinical status after the treatment period.

Evidence in Special Patient Populations

Research has tracked outcomes for children with AOM and has included specific studies on older adults who required hospitalization for CAP. Data for certain groups remain insufficient, particularly concerning the effects on pregnancy-related populations where information is often predicted rather than directly measured in clinical trials. Research is ongoing to determine if specialized dosing strategies were associated with different outcomes for critically ill patients.

What is Still Uncertain About Novaclav Research

Evidence is limited in certain key areas, such as robust head-to-head comparisons against all currently available treatment options for CAP. The available data show patterns related to the risk of patient-reported outcomes describing perceived discomfort when comparing the combination product to amoxicillin alone. It is important to recognize that results apply only to the populations studied, and research does not determine whether an individual will respond similarly.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Novaclav (FAQ)


Q: Does Novaclav have the same active ingredients as Augmentin?

A: Yes. Novaclav is a brand name for the combination of amoxicillin and clavulanic acid. These are the same two active ingredients found in the brand-name medicine Augmentin.


Q: Is Novaclav a broad-spectrum antibiotic?

A: Official product information, such as the European Summary of Product Characteristics, classifies the amoxicillin and clavulanic acid combination as a broad-spectrum antibacterial product. This means it is designed to be effective against a wide range of bacteria.


Q: What is the main difference between Novaclav and amoxicillin alone?

A: Novaclav contains two active ingredients: amoxicillin (the antibiotic) and clavulanic acid (an inhibitor). The clavulanic acid is included specifically to protect the amoxicillin from being broken down by bacterial defense enzymes (beta-lactamases). This protective role extends the range of bacteria that the medicine can potentially combat.


Q: Why is clavulanate potassium added to amoxicillin in Novaclav?

A: Clavulanate potassium acts as a beta-lactamase inhibitor. Its primary role is to chemically neutralize bacterial defense enzymes that would otherwise inactivate the amoxicillin component. This pairing allows the antibiotic to maintain its effectiveness against resistant infections.


Q: How long do people typically take Novaclav?

A: According to official product information, the usual course of therapy is described as lasting 7 to 10 days. The treatment is generally not recommended to be extended beyond 14 days without a medical review.


Q: How is Novaclav described in official government drug agency documents?

A: Official documents, such as the FDA label, describe Novaclav as an oral antibacterial combination. It consists of the semisynthetic antibiotic amoxicillin and the beta-lactamase inhibitor, clavulanate potassium, indicated for specific types of bacterial infections.


Q: Can Novaclav be used for treating common colds or flu?

A: This medication is indicated for the treatment of bacterial infections. Regulatory guidance confirms that antibiotics, including Novaclav, will not work against viral infections such as the common cold or flu.


Q: Is it important to finish all of the Novaclav prescribed?

A: Official patient counseling emphasizes the importance of taking the medicine exactly as directed by the prescribing professional. This guidance is in place to ensure proper use during the course of therapy.


Q: What does the term 'antibiotic resistance' mean in relation to Novaclav?

A: The FDA label stresses the importance of using this drug only for proven or strongly suspected bacterial infections. This is done to help reduce the development of drug-resistant bacteria, which means the bacteria are no longer susceptible to the medicine’s effects.


Q: Are there any food restrictions mentioned in official documents for Novaclav?

A: There are no specific food restrictions listed in regulatory documents. However, it is recommended to take the medicine at the start of a meal, as this timing is intended to enhance absorption and minimize the potential for gastrointestinal intolerance.


Q: Why does Novaclav sometimes cause stomach upset?

A: The drug is known to potentially cause gastrointestinal intolerance, such as stomach upset. Official patient counseling recommends taking the medicine at the start of a meal, as this practice may help to minimize this known side effect.


Q: What is the risk of developing C. difficile associated with Novaclav use?

A: Antibiotic-associated colitis, including C. difficile associated diarrhea, is listed in the official documents as a potential adverse reaction. This complication is reported as occurring with an unknown frequency.


Q: How long after stopping Novaclav do the ingredients stay in the body?

A: Pharmacokinetic data in the FDA label indicate that the half-life (the time it takes for half of the substance to be eliminated) of the amoxicillin component is approximately 1.3 hours, and the half-life of the clavulanic acid component is approximately 1.0 hour.


Q: What happens if Novaclav is taken past its expiration date?

A: The expiration date is the last day the manufacturer guarantees the medication’s safety and potency. Taking the medicine past this date is not recommended in official guidance due to the potential for the product to lose its expected effectiveness.


Q: Does Novaclav lose its effectiveness if stored improperly?

A: Official storage instructions mandate specific conditions (such as refrigeration for the liquid suspension) that are necessary to guarantee the medication’s stability, safety, and effectiveness. Improper storage may compromise these critical properties.


Q: Is there a generic version of Novaclav available?

A: Yes. The active ingredients, amoxicillin and clavulanate potassium, are widely available as a generic drug in the United States.


Q: Can Novaclav be used to prevent an infection before a surgical procedure?

A: Official guidance confirms the drug is indicated to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.


Q: Does Novaclav treat sexually transmitted infections (STIs)?

A: As a broad-spectrum antibiotic, this medicine is used to treat a variety of bacterial infections. The general class of antibiotics is used for treating some STIs, though the Novaclav label itself does not specifically list STIs as an indication.


Q: Is Novaclav described as safe for use during pregnancy in official sources?

A: The drug is classified as Pregnancy Category B. This classification indicates that animal reproduction studies have shown no risk to the fetus, but there are no adequate and well-controlled studies conducted in pregnant women.


Q: What are the official guidelines regarding Novaclav use and breastfeeding?

A: Official product information states that both amoxicillin and clavulanic acid are excreted in human milk. Use during breastfeeding should only occur after the responsible physician performs a formal benefit-risk assessment.


Q: Does the efficacy of Novaclav change if it's taken after a large meal?

A: Regulatory information states that the absorption of the clavulanate component is enhanced when the medicine is administered at the start of a meal. Taking it at a different time might result in reduced bioavailability of the clavulanate.


Q: Do studies support Novaclav's use for treating ear infections?

A: Yes. The combination is indicated for the treatment of Acute Bacterial Otitis Media (AOM) in adults and children. Clinical studies established its effectiveness against susceptible bacteria causing this condition.


Q: Why do some people experience yeast infections when taking Novaclav?

A: Mucocutaneous candidosis (thrush) is listed as a common side effect. This is because, like other antibiotics, Novaclav can disrupt the natural balance of microorganisms in the body, which may allow non-susceptible organisms like yeast to overgrow.


Q: Does Novaclav cause drowsiness or affect driving ability?

A: No specific studies on driving ability are listed in official documents. However, undesirable effects such as dizziness or convulsions may occur, and patients are advised that these effects could influence their ability to drive or operate machinery.


Q: What high-level evidence themes are reported in clinical trials for Novaclav?

A: Clinical trials for Novaclav report evidence related to bacterial eradication rates and clinical success or resolution status. These measured outcomes track how well the drug works against the specific bacterial infections listed in its indications.


Q: Is the side effect profile of Novaclav different for children versus adults?

A: The drug label notes that hepatic events (liver problems) are very rarely reported in children. Conversely, these events are reported predominantly in older patients and males, indicating some differences in the side effect frequency by age.


Q: Are there specific symptoms that require immediate medical attention while taking Novaclav?

A: Official safety information advises that symptoms of serious hypersensitivity reactions (such as swelling of the face, difficulty breathing, or rash) or severe hepatic dysfunction (like jaundice) require immediate medical attention.

Advertisements

How should Novaclav be stored and disposed of?

Storage and Disposal Requirements for Novaclav

Official regulatory guidelines for Novaclav (amoxicillin and clavulanate potassium) vary significantly by dosage form.


Storage Conditions

  • Tablets: Must be stored at controlled room temperature (20 C to 25 C) and kept away from excess heat and moisture. Keep in the original, tightly closed container.
  • Suspension (Liquid): The reconstituted suspension must be stored in a refrigerator (2 C to 8 C) and must not be frozen. It is stable for 10 days under refrigeration, after which any unused portion must be discarded.

Disposal Instructions

To dispose of expired or unused medication, utilize a drug take-back program if available. If not, mix the drug with an undesirable substance (e.g., used coffee grounds) in a sealed bag before disposal in household trash. Do not flush the medicine down the toilet or pour it down a drain. All forms must be stored out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Novaclav found in:

A-Z Index: